Open Clinical Trial Data for All? A View from Regulators by Eichler, Hans-Georg et al.
Perspective







1European Medicines Agency (EMA), London, United Kingdom, 2Agence Franc ¸aise de Se ´curite ´ Sanitaire des Produits de Sante ´ (AFSSAPS) Saint-Denis, France, 3Medicines
and Healthcare products Regulatory Agency (MHRA), London, United Kingdom, 4Medicines Evaluation Board (CBG-MEB), Den Haag, The Netherlands
In this issue of PLoS Medicine, Doshi and
colleagues argue that the full clinical trial
reports of authorized drugs should be
made publicly available to enable inde-
pendent re-analysis of drugs’ benefits and
risks [1]. We offer comments on their call
for openness from a European Union drug
regulatory perspective.
For the purpose of this discussion, we
consider ‘‘clinical study reports’’ to com-
prise not just the protocol, summary
tables, and figures of (mostly) randomized
controlled trials (RCTs), but the full ‘‘raw’’
data set, including data at the patient level
[2]. We limit discussion to data on drugs
for which the regulatory benefit-risk as-
sessment has been completed.
Why Trial Data Should Be Open
for All
First and foremost, we agree with
Doshi et al. that clinical trial data should
not be considered commercial confiden-
tial information; most patients enrolling
in clinical trials do so with an assumption
of contributing to medical knowledge,
and ‘‘non-disclosure of complete trial
results undermines the philanthropy’’
[1].
The potential benefits for public health
of independent (re-)analysis of data are not
disputed and, in an open society, trial
sponsors and regulators do not have a
monopoly on analyzing and assessing drug
trial results. Yet, the different responsibil-
ities of regulators and independent ana-
lysts have to be acknowledged. Regulators,
unlike academicians, are legally obliged to
take timely decisions on the availability of
drugs for patients, even under conditions
of uncertainty.
Going beyond the merits of indepen-
dent meta-analysis, we foresee other,
potentially more important benefits from
public disclosure of raw trial data. For
example, RCT datasets enabled the de-
velopment of predictive models for patient
selection to appropriate treatments [3,4].
Taking this notion a step further, we
envisage machine learning systems that
will allow clinicians to match a patient’s
electronic health record directly to RCT
and observational study data sets for
better, individualized therapeutic decisions
(L. Perez-Breva, personal communica-
tion).
Large, information-rich datasets are
needed to support the computer science
and artificial intelligence research re-
quired to develop and test these applica-
tions. Developing such tools is usually not
a priority for, and often beyond the
capabilities and resources of, even the
largest pharmaceutical companies. These
endeavors might best thrive in an envi-
ronment that invites research from be-
yond the current stakeholders in health
[5]. Making rich datasets available for
research is a means to open health
research.
Why Trial Data Should Not Be
Open for All
There are indeed many good arguments
for unrestricted and easy access to full
RCT data. Yet, simply uploading all trial
data on a website would entail its own
problems.
First among those is the issue of
personal data protection or patient confi-
dentiality, a concept that is very different
from commercial confidentiality. There is a
small risk that personal data could inad-
vertently be publicized. There is also a
small risk that an individual patient could
be identified from an anonymized dataset,
for example, from trials in ultra-rare
diseases. Achieving an adequate standard
of personal data protection is not an
insurmountable obstacle, though, and
proposals for best practice for publishing
raw data are available [2]. However,
implementation is not straightforward,
standards will need to be agreed upon up
front, and data redaction may in a few
cases be resource intensive.
Our second caveat is likely more
contentious. We do not dispute that
financial conflicts of interests (CoIs) may
render analyses and conclusions ‘‘vulner-
able to distortion’’ [1]. However, sur-
rounding the ongoing debate over spon-
sor-independent analyses is an implicit
assumption that ‘‘analysis by independent
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Linked Policy Forum
This Perspective discusses the fol-
lowing new Policy Forum published
in PLoS Medicine:
Doshi P, Jefferson T, Del Mar C
(2012) The Imperative to Share
Clinical Study Reports: Recommen-
dations from the Tamiflu Experi-
ence. PLoS Med 9(4): e1001201.
doi:10.1371/journal.pmed.1001201
Peter Doshi and colleagues de-
scribe their experience trying and
failing to access clinical study
reports from the manufacturer of
Tamiflu and challenge industry to
defend their current position of
RCT data secrecy.
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beg to differ. Personal advancement in
academia, confirmation of previously de-
fended positions, or simply raising one’s
own visibility within the scientific commu-
nity may be powerful motivators. In a
publish-or-perish environment, would the
finding of an important adverse or favor-
able drug effect at the p,0.05-level be
more helpful to a researcher than not
finding any new effects? Will society
always be guaranteed that a finding that
is reported as ‘‘confirmatory’’ was not the
result of multiple exploratory re-runs of a
dataset? We submit that analyses by
sponsor-independent scientists are not
generated in a CoI-free zone and, more
often than not, ego trumps money.
Independent analyses may therefore also
be ‘‘vulnerable to distortion’’. We are
concerned that unrestricted availability of
full datasets may in some cases facilitate
the publication of papers containing mis-
leading results, which in turn lead to
urgent calls for regulatory action. In a
worst case, this would give rise to un-
founded health scares with negative public
health consequences such as patients
refusing vaccinations or discontinuing
drug treatment [6,7].
Aside from CoIs, independent analysis
per se is no guarantee of high quality. The
regulatory community has been confront-
ed with meta-analyses that were later
contradicted by additional evidence [8]
or found to be flawed [9]. We argue that
independent analyses warrant a similar
level of scrutiny as sponsor-conducted
analyses do.
Finally, re-analysis of trial data could be
misused for competitive purposes.
The Way Forward?
We consider it neither desirable nor
realistic to maintain the status quo of
limited availability of regulatory trials
data. What is needed is a three-pronged
approach:
1. Develop and agree upon adequate
standards for protection of personal
data when publicizing RCT datasets.
Most stakeholders will likely agree that
adequate standards of data protection
are a sine qua non, so the issue should be
primarily of a technical and legal
nature. We emphasize adequate stan-
dards because excessive demands and
unrealistically high standards may in
effect become an ‘‘anti-commons’’ and
frustrate important public health gains.
2. Ensure general adoption of established
quality standards of meta-analyses and
other types of (confirmatory) data re-
analysis that may warrant regulatory
action.
3. Establish rules of engagement: In the
area of observational studies based on
health care databases, the European
Network of Centres for Pharmacoepi-
demiology and Pharmacovigilance
(ENCePP) has recently published guid-
ance for raw data sharing; these rules
of engagement follow the principle of
maximum transparency whilst respect-
ing the need to guarantee data privacy
and to avert the potential for misuse
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broadly similar proposals [11]. Con-
ceivably, analogous principles (e.g.,
data sharing only after receipt of a full
analysis plan) could be applied to
regulatory RCT data [1].
Moreover, we take it as self-evident that
the same standard of openness should
apply to all (drug) trial data, whether
sponsored by industry, investigator-initiat-
ed, or sponsored by public grant-giving
bodies. Likewise, the same standard of
third party scrutiny should be applicable
to all secondary data analyses. Regulatory
inspections of data and analyses carried
out by commercial sponsors are routine.
Would all sponsor-independent research-
ers allow the same level of inspections
applied to their analyses?
We welcome debate on these issues, and
remain confident that satisfactory solutions
can be found to make complete trial data
available in a way that will be in the best
interest of public health.
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